Table 1.
The baseline characteristics of the ICIs cohort.
| Patients (n = 143) | |
|---|---|
| Sex | |
| Male | 119 (83.2) |
|
| |
| Age (year) | |
| ≥65 | 57 (39.9) |
|
| |
| Smoking status | |
| Nonsmoker | 37 (25.9) |
| Smoker | 106 (74.1) |
|
| |
| Histology | |
| Adenocarcinoma | 73 (51.0) |
| Squamous | 61 (42.7) |
| NSCLC-others | 9 (6.3) |
|
| |
| KRAS alteration status | |
| KRAS wild-type | 65 (45.5) |
| KRAS mutant | 6 (4.2) |
| NA | 72 (50.3) |
|
| |
| PD-L1 status | |
| Negative | 8 (5.6) |
| Positive | 24 (16.8) |
| NA | 111 (77.6) |
|
| |
| PS (ECOG) | |
| 0-1 | 141 (98.6) |
| ≥2 | 2 (1.4) |
|
| |
| Stage | |
| I-II | 7 (4.9) |
| IIIA | 9 (6.3) |
| IIIB–IV | 127 (88.8) |
|
| |
| Metastatic sites number | |
| <2 | 57 (39.9) |
| ≥2 | 86 (60.1) |
|
| |
| Metastatic sites | |
| Live | 18 (12.6) |
| Bone | 34 (23.8) |
| Brain | 19 (13.3) |
| WBC (×109/L) | 6.62 (5.51–8.87) |
| ANC (×109/L) | 4.36 (3.09–6.01) |
| ALC (×109/L) | 1.46 (1.02–1.82) |
| MON (×109/L) | 0.59 (0.42–0.81) |
| RDW (%) | 13.8 (13.1–15.0) |
| PLT (×109/L) | 230 (174–296) |
| ALB (g/L) | 40.89 ± 4.85 |
| PLR | 155.62 (117.56–227.74) |
| dNLR | 2.08 (1.45–2.74) |
|
| |
| ICIs drug | |
| Sintilimab | 20 (14.0) |
| Nivolumab | 37 (25.9) |
| Pembrolizumab | 86 (60.1) |
|
| |
| ICIs treatment modality | |
| ICI monotherapy | 46 (32.2) |
| ICI + chemotherapy | 87 (60.8) |
| ICI + antiangiogenic | 10 (7) |
|
| |
| ICIs line | |
| 1 | 46 (32.2) |
| ≥2 | 97 (67.8) |
|
| |
| Previous treatments before ICIs | |
| Chemotherapy | 89 (62.2) |
| Radiotherapy | 23 (16.1) |
| EGFR-TKI | 12 (8.4) |
| Antiangiogenic | 25 (17.5) |
| Surgery | 13 (9.1) |
|
| |
| Disease response | |
| CR | 2 (1.4) |
| PR | 60 (42.0) |
| SD | 55 (38.5) |
| PD | 26 (18.2) |
|
| |
| Response rates | |
| ORR (%) | 43.4 |
| DCR (%) | 81.8 |
NA, not assessable; MON, monocyte.